Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies

BioSeeker Group AB
March 19, 2013
5072 Pages - SKU: BIOS5014693
Antibodies in Oncology: Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
Antibodies in Oncology: Drug Pathway Analyzer 2014 Extra value: One year of free online updates included with this product There are today at least 608 antibody drugs known to affect more than 206 specific intracellular signaling pathways  |  read more...
USD 6,746
Antibodies in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
Antibodies in Oncology Drug Pipeline Update 2014 The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the  |  read more...
USD 6,746
Cancer Vaccines Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
Cancer Vaccines Drug Pipeline Update 2014 Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving  |  read more...
USD 6,746
Conference Documentation: ADC Summit 2014
5/19/2014 | published by: SMI Publishing, Ltd
Conference Documentation: ADC Summit 2014 SMi Group is proud to announce that the ADC Summit 2013 conference will be returning to London in 2014. If you are interested in getting involved, please contact Dale Butler  |  read more...
USD 788
Chronic Lymphocytic Leukaemia: KOL Insight
5/27/2014 | published by: FirstWord
Introduction Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and targeted  |  read more...
USD 4,995
Antibody Partnering Terms and Agreements
6/1/2014 | published by: Current Partnering
Antibody Partnering Terms and Agreements Report scope  |  read more...
USD 2,995
The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition
9/22/2013 | published by: Kalorama Information
The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin,  |  read more...
USD 2,995
Single-use Bioreactors Market, 2014-2024
4/23/2014 | published by: Roots Analysis
Single-use Bioreactors Market, 2014-2024 There is widespread optimism that the single-use bioreactors market is likely to continue its double digit growth in the future. The concept of “single-use technology”, which started in 1970s with  |  read more...
USD 1,899
Drug Delivery Technologies Market Forecast 2014-2024
4/30/2014 | published by: Visiongain
Drug Delivery Technologies Market Forecast 2014-2024 Drug Delivery Technologies - new study showing you trends, R&D progress, and predicted revenues Where is the drug delivery technologies market heading? What are the commercial prospects  |  read more...
USD 2,986
Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors
2/28/2014 | published by: La Merie Publishing
Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors TNF Antibodies –Biosimilars and Biosuperiors The present Competitive Intelligence Report about TNF Antibodies –Biosimilars and  |  read more...
USD 555
 

SELECT A LICENSE

    PDF E-mail From Publisher  USD 5,175  
    Global Site License Fulfilled by Publisher  USD 12,937  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!